Searchable abstracts of presentations at key conferences in endocrinology

ea0035p812 | Paediatric endocrinology | ECE2014

Pediatric Graves disease: treatment options and prognosis factors

Saraiva Joana , Cardoso Rita , Dinis Isabel , Gomes Leonor , Carrilho Francisco , Mirante Alice

Introduction: Graves’ disease (GD) is the most common cause of hyperthyroidism in children. Therapeutic options available (anti-thyroid drugs, radioactive iodide, and thyroidectomy) are associated with complications and treatment of this age group remains controversial.Objective: To review our experience in the management of pediatric patients with GD.Materials and methods: Retrospective review of 35 children, diagnosed betwee...

ea0035p944 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Weight and metabolic profile evolution in patients with treated prolatinomas

Guelho Daniela , Gomes Leonor , Paiva Isabel , Saraiva Joana , Moreno Carolina , Cardoso Luis , Vicente Nuno , Carrilho Francisco

Introduction: The metabolic consequences of hyperprolactinemia and the repercussions of its treatment with dopaminergic agonists are not yet fully understood. This study aims to evaluate the metabolic profile of patients with prolactinomas (prevalence of diabetes mellitus, dyslipidaemia and obesity) and identify the potential variations after treatment with bromocriptine.Methods: Retrospective study of patients followed between 1962 and 2013. Included 17...

ea0035p1074 | Thyroid (non-cancer) | ECE2014

High-resolution thyroid nodule clinic: analysis of 1674 thyroid nodules

Fernandez-Garcia Jose Carlos , Cortes-Salazar Carmen Maria , Mancha-Doblas Isabel , Tinahones Francisco

Background and objectives: The finding of a thyroid nodule is a very common occurrence in clinical practice. Management of thyroid nodules requires a multidisciplinary approach that may be eased by a high-resolution thyroid nodule clinic. We report our clinical experience and outcomes in a high-resolution thyroid nodule clinic.Materials and methods: We conducted a retrospective analysis of 1674 thyroid nodules evaluated in a high-resolution clinic from a...

ea0070oc1.4 | Adrenal and Cardiovascular Endocrinology | ECE2020

Immune infiltrate and PD-1 / PD-L1 expression in adrenocortical carcinoma: who can predict patients´ outcome?

Landwehr Laura-Sophie , Sbiera Iuliu , Schreiner Jochen , Weigand Isabel , Kroiss Matthias , Fassnacht Martin , Sbiera Silviu

Context: Adrenocortical carcinoma (ACC) are endocrine malignant neoplasms associated with severe aggressiveness. Tumour-related glucocorticoid excess occurs in 60% of patients and is associated with poor prognosis. First clinical trials using immune checkpoint inhibitors are quite unsatisfactory and treatment advancements are urgently needed.Recently, we characterized tumour-infiltrating lymphocytes (TILs) in ACC and identified the detrimental dependency...

ea0070aep83 | Adrenal and Cardiovascular Endocrinology | ECE2020

JIL-O: Establishment of a new steroidogenic human adrenocortical carcinoma cell line

Landwehr Laura-Sophie , Jochen Schreiner , Herterich Sabine , Appenzeller Silke , Fassnacht Martin , Kroiss Matthias , Weigand Isabel

Adrenocortical carcinoma (ACC) is a rare malignancy with heterogeneous but dismal prognosis and despite numerous efforts to improve patient care, effective treatment options are still lacking. ACC in vitro research faces for decades one major obstacle - the unavailability of different ACC cell line models. Here, we present a newly established human ACC cell line that was directly transferred to and now proliferates in cell culture. JIL-O cell line was derived from a p...

ea0070aep486 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Glycemic variability in type 1 diabetes

Santos Tiago , Inácio Isabel , Soares Bruno , Vilaverde Joana , Teixeira Sofia , Cardoso Helena

Introduction: Glycemic variability (GV) is emerging as a measure of glycemic control in type 1 diabetic patients (T1DM) given that it provides an integrated picture of postprandial hyperglycemia and hypoglycemic episodes and is associated with diabetic complications and mortality. However, little is known about the best way to address this problem in clinical practice.Aim: To characterize GV in T1DM patients followed in our center and to identify clinica...

ea0070aep646 | Pituitary and Neuroendocrinology | ECE2020

Differences in acquired and idiopathic adult-onset growth hormone deficiency

Yee Cheng Boey , Gill Lizy , Brown Sarah , Palau Isabel , Allie Nicole

Introduction: Growth hormone deficiency (GHD) is a medical condition affecting adults and children who lack sufficient growth hormone. The objective of this study was to compare diagnoses in acquired and idiopathic adult-onset GHD patients.Methodology: Results are from Ipsos’ EU5 GHD Therapy Monitor Study 2018, which is an online study conducted among physicians treating both paediatric and adult GHD patients. 156 sampled physicians provided d...

ea0032p144 | Calcium and Vitamin D metabolism | ECE2013

Primary hypoparathyroidism and autoimmune endocrine disorders

Martins Ana , Martins Joao Martin , Vale Sonia , Gomes Ana , Miltenberger-Miltenyi Gabriel , Carmo Isabel

Introduction: Primary hypoparathyroidism (PH) is a rare condition. After surgery and chronic alcoholism, an autoimmune disease is the most common etiology and must specifically be considered in the context of a patient with other autoimmune endocrine diseases.Case report: MASD a male caucasian patient aged 31, was admitted to the emergency department because of perioral and hand paresthesias, and carpal spasm, in the context of a generalized anxiety reac...

ea0032p202 | Cardiovascular Endocrinology &amp; Lipid Metabolism | ECE2013

Dyslipidemia associated with m-TOR inhibitors treatment

Couto Joana , Martins Raquel , Carneiro Filipa , Santos Ana Paula , Torres Isabel

Introduction: Therapeutic approach of patients (pts) with metastatic renal cell carcinoma (mRCC) may include the use of biological agents such as m-TOR inhibitors: temsirolimus (TM) and everolimus (EV). Its use is associated with metabolic dysfunction, especially with everolimus: hyperglycemia (37% TM treated pts vs 72% EV treated pts), hypercholesterolemia (25% TM treated pts vs 81% EV treated pts) and hypertriglyceridemia (30% TM treated pts vs 73% EV treated pts). Discontin...

ea0032p273 | Clinical case reports - Thyroid / Others | ECE2013

Familial Graves’ disease: case report

Mota Ana , Martins Joao , Vale Sonia , Martins Ana , Gomes Ana , Miltenberger-Miltenyi Gabriel , Carmo Isabel

Introduction: Graves’ disease is an autoimmune condition with an estimated prevalence of about 2%, 5–10 times more frequent in females. A multifactorial nature is assumed, with genetic contribution accounting for up to 80% of the variability. Relevant genes includegeneral autoimmune risk loci, such as the HLA region, CTLA-4, PTPN22 and CD40, as well as thyroid-specific loci (thyroglobulin and TSH receptor genes). We report a particular case of Graves’ d...